ISB 2001
An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug.
Overview
ISB 2001 is a trispecific antibody from Ichnos Glenmark Innovation that binds BCMA and CD38 on multiple myeloma cells and CD3 on T cells, with the aim of engaging tumours that express either antigen at low levels and reducing escape through single-antigen loss. It has been in phase 1 for relapsed or refractory multiple myeloma with orphan drug designation in the US. In July 2025 AbbVie licensed it for North America, Europe, Japan and Greater China for 700 million dollars upfront and up to 1.225 billion dollars in milestones plus royalties, with Glenmark retaining India and emerging markets. It is the clearest sign that Indian discovery, not only manufacturing, is entering global oncology.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"ISB 2001" OR ABSTRACT:"ISB 2001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ISB 2001, not a curated reading list.
Pages like this
not linked directly; found by shared links- PersonPhilippe Moreau
Shares Teclistamab, CD38, BCMA, Bispecific antibodies.
- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares Talquetamab, Teclistamab, BCMA, Multiple myeloma.
- PersonAjai Chari
Shares CD38, Bispecific antibodies, T-cell engagers (bispecific), Multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares Talquetamab, Teclistamab, BCMA, Bispecific antibodies.
- Key paperMagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response
Shares Talquetamab, Teclistamab, BCMA, Bispecific antibodies.
- PersonSaad Z. Usmani
Shares Teclistamab, BCMA, T-cell engagers (bispecific), Multiple myeloma.
- InstitutionComprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Teclistamab, BCMA, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyCullinan Therapeutics
Shares BCMA, Bispecific antibodies, T-cell engagers (bispecific).